Developer docs
API playgroundTry for free, no card

Search company profiles

Biolinq

Full company profile

uuid00004kv

Namestring
Biolinq
Legal namestring
Biolinq Incorporated
Websiteurl
biolinq.com
Company typeenum
Private
Founded yearint
2012
Descriptiontext

Biolinq Incorporated is a San Diego-based healthcare technology company founded in 2012 that has developed an intradermal wearable biosensor platform. Its flagship product, Biolinq Shine, is a needle-free continuous glucose monitor whose microsensor array sits approximately 0.2 mm below the skin surface in the papillary dermis — roughly 20 times shallower than conventional CGM sensors — and is manufactured using semiconductor processes. The device integrates glucose sensing with an accelerometer and ambient light sensor, displays real-time glucose status via a color-coded LED (blue for in-range, yellow for elevated), and pairs with a mobile app that correlates glucose with meals, rest, and activity. On September 25, 2025, the FDA granted De Novo Classification for Biolinq Shine for over-the-counter use in adults 22 and older with Type 2 diabetes not on insulin therapy, establishing a new regulatory category for autonomous, needle-free glucose sensors with integrated primary displays.

The company is preparing to commercialize the device primarily through direct-to-consumer e-commerce and pharmacy retail channels, with an initial focus on people with Type 2 diabetes not on insulin and a secondary target of health-conscious consumers seeking metabolic and lifestyle insight. Revenue mechanics are expected to follow a hardware-plus-disposable model with recurring sensor replacement cycles, although pricing has not been publicly disclosed. The platform is architecturally designed for multi-analyte expansion to additional biomarkers such as lactate and cortisol.

Biolinq has raised approximately $300 million across multiple funding rounds (Series A in 2017, Series B in 2021, bridge financing in 2024, and Series C in April 2025), with Alpha Wave Ventures leading the most recent two rounds. The management team is dominated by former Dexcom and Medtronic Diabetes executives, and the board includes representatives from Alpha Wave Ventures, AXA IM Alts, RiverVest Venture Partners, and UnitedHealthcare.

Short descriptiontext

Biolinq is a San Diego-based medical device company developing Biolinq Shine, an FDA-cleared (De Novo, September 2025) needle-free, intradermal continuous glucose monitor with an integrated LED display, targeting adults with Type 2 diabetes not on insulin and health-conscious consumers through OTC and direct-to-consumer channels.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersSan Diego, United States
HQ citystring
San Diego
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
continuous glucose monitoring, wearable biosensors, metabolic health devices, needle-free sensors, diabetes monitoring technology
Industry4 codes
PRIMARYHLAHAHAA
Continuous Glucose Monitoring (CGM) Systems
Healthcare & Life Sciences/Medical Devices & Diagnostics/Diabetes Care Devices (CGM, Insulin Delivery)
SECONDARYCRACAQAE
Blood Glucose Monitoring Devices (Consumer CGM & Smart Glucometers)
Consumer Products & Retail/Consumer Electronics & Appliances Retail/Personal Health & Wellness Devices (Smart Scales, BP/ECG Monitors, Sleep Devices)
SECONDARYHLAHAHAL
Diabetes Care Device Accessories & Adhesives (Sensors/Pump Supplies)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Diabetes Care Devices (CGM, Insulin Delivery)
SECONDARYHDAHALAK
Biosensors & Lab-on-Chip (BioMEMS)
NAICS code3 codes
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Other Measuring and Controlling Device Manufacturing334519
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code3 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Electromedical & Electrotherapeutic Apparatus3845
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Wearable Continuous Glucose Monitoring
Social media profiles3 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Biolinq Shine Glucose Sensor
TypeHardware Sales
Description

Wearable biosensor sold as a disposable device with continuous glucose monitoring capability. Revenue expected from device sales, likely with recurring disposable sensor replacement cycle. Initially targeted at adults with Type 2 diabetes not on insulin therapy.

biolinq.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure
GTM typeB2C
B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1Biolinq Shine
Description

First fully autonomous, needle-free glucose sensor with integrated LED display for real-time glucose feedback, combining glucose, activity, and sleep monitoring in a single device for people with Type 2 diabetes not on insulin therapy.

biolinq.com
Core offering1 text field

Biolinq develops and commercializes the Biolinq Shine, a needle-free wearable continuous glucose monitoring (CGM) biosensor. The device uses an intradermal electrochemical microsensor array positioned in the papillary dermis layer (approximately 0.2mm deep, 20x more shallow than conventional CGM sensors) to measure glucose from interstitial fluid without hypodermic needles. It integrates a color-coded LED display (blue/yellow) for real-time glucose status and automatically correlates glucose data with activity and sleep tracking. The product received FDA De Novo classification in September 2025, establishing a new regulatory category of autonomous wearable glucose sensors.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • First needle-free glucose sensor with integrated primary display receiving FDA De Novo classification
+2 more records
Product overview1 text field

Biolinq is a healthcare technology company pioneering precision multi-analyte wearable biosensors to improve metabolic health. The company's flagship product is the Biolinq Shine biosensor, a needle-free continuous glucose monitoring wearable that integrates glucose, activity, and sleep data in a single device. The system consists of the Biolinq Shine hardware sensor with an autonomous LED display and a companion mobile application that provides detailed trend analysis and personalized insights. The platform is designed for multi-analyte sensing expansion beyond glucose to include biomarkers such as lactate and cortisol.

Product and service1 record
1Biolinq Shine
CategoryWearable Continuous Glucose Monitoring Device
Description

A needle-free wearable biosensor that continuously monitors glucose levels using an array of microsensors up to 20 times more shallow than conventional continuous glucose sensors. Features an integrated LED color-coded display (blue for in-range, yellow for elevated) visible without a phone, and automatically tracks activity and sleep data. Designed for adults 22 years or older with type 2 diabetes not on insulin therapy.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-10-16
Description

Amalgam Rx partnered with Biolinq to develop digital infrastructure for Biolinq Shine. Amalgam's platform enabled rapid software development supporting Biolinq's FDA regulatory process and future expansion plans for connected health solutions and personalized care.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Dexcom is the U.S. market leader in continuous glucose monitoring, offering G6 and G7 CGM systems. Directly comparable as a CGM device maker targeting diabetes patients with needle-based wearable sensors, though serving broader populations including insulin-dependent users.

2Abbott (FreeStyle Libre)
TypeDirect peer
Description

Abbott's FreeStyle Libre is the global volume leader in CGM with factory-calibrated sensors. Direct competitor in the wearable glucose monitoring category, with a substantial non-insulin T2D user base that Biolinq also targets.

TypeBroad incumbent
Description

Medtronic offers the Guardian CGM system integrated with its insulin pumps and closed-loop diabetes management portfolio. Broad incumbent in diabetes devices; former employer of Biolinq CEO Rich Yang.

TypeDirect peer
Description

Senseonics develops Eversense, the first long-term implantable CGM with a 180-day sensor. Direct peer pursuing an alternative-format CGM approach with extended wear time, competing for differentiated glucose monitoring share.

TypeEmerging player
Description

Nemaura is developing sugarBEAT, a non-invasive continuous glucose monitor using a skin patch. Emerging player pursuing needle-free CGM with partial overlap to Biolinq's needle-free approach.

TypeBroad incumbent
Description

Ascensia is a focused diabetes care company offering CONTOUR blood glucose monitoring systems. A Series B investor in Biolinq and a broad incumbent in the diabetes monitoring category.

TypeBroad incumbent
Description

Insulet makes the Omnipod tubeless insulin pump, an adjacent diabetes management device. Broad incumbent in diabetes care delivery with potential ecosystem overlap with CGM data.

TypeBroad incumbent
Description

Tandem develops the t:slim insulin pump with CGM integration for automated insulin delivery. Broad incumbent in diabetes management and a potential integration partner for Biolinq's data streams.

TypeBroad incumbent
Description

Roche offers the Accu-Chek portfolio of blood glucose monitors and insulin delivery systems. Broad incumbent in diabetes monitoring with established pharmacy and payer channels relevant to Biolinq's OTC strategy.

TypeEmerging player
Description

EOFlow develops the EOPatch tubeless insulin pump and participated as an investor in Biolinq's Series B. Emerging player in wearable drug delivery with potential ecosystem partnership in diabetes care.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles18 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds9 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors29 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Biolinq

Wearable Continuous Glucose Monitoringbiolinq.com

Biolinq is a San Diego-based medical device company developing Biolinq Shine, an FDA-cleared (De Novo, September 2025) needle-free, intradermal continuous glucose monitor with an integrated LED display, targeting adults with Type 2 diabetes not on insulin and health-conscious consumers through OTC and direct-to-consumer channels.

What Biolinq does

Biolinq Incorporated is a San Diego-based healthcare technology company founded in 2012 that has developed an intradermal wearable biosensor platform. Its flagship product, Biolinq Shine, is a needle-free continuous glucose monitor whose microsensor array sits approximately 0.2 mm below the skin surface in the papillary dermis — roughly 20 times shallower than conventional CGM sensors — and is manufactured using semiconductor processes. The device integrates glucose sensing with an accelerometer and ambient light sensor, displays real-time glucose status via a color-coded LED (blue for in-range, yellow for elevated), and pairs with a mobile app that correlates glucose with meals, rest, and activity. On September 25, 2025, the FDA granted De Novo Classification for Biolinq Shine for over-the-counter use in adults 22 and older with Type 2 diabetes not on insulin therapy, establishing a new regulatory category for autonomous, needle-free glucose sensors with integrated primary displays.

The company is preparing to commercialize the device primarily through direct-to-consumer e-commerce and pharmacy retail channels, with an initial focus on people with Type 2 diabetes not on insulin and a secondary target of health-conscious consumers seeking metabolic and lifestyle insight. Revenue mechanics are expected to follow a hardware-plus-disposable model with recurring sensor replacement cycles, although pricing has not been publicly disclosed. The platform is architecturally designed for multi-analyte expansion to additional biomarkers such as lactate and cortisol.

Biolinq has raised approximately $300 million across multiple funding rounds (Series A in 2017, Series B in 2021, bridge financing in 2024, and Series C in April 2025), with Alpha Wave Ventures leading the most recent two rounds. The management team is dominated by former Dexcom and Medtronic Diabetes executives, and the board includes representatives from Alpha Wave Ventures, AXA IM Alts, RiverVest Venture Partners, and UnitedHealthcare.

Biolinq firmographics

Firmographics
Name
Biolinq
Legal name
Biolinq Incorporated
Website
https://biolinq.com
Company type
Private
Founded year
2012
Operating status
Operating
Headcount range
101–250 employees
Short description
Biolinq is a San Diego-based medical device company developing Biolinq Shine, an FDA-cleared (De Novo, September 2025) needle-free, intradermal continuous glucose monitor with an integrated LED display, targeting adults with Type 2 diabetes not on insulin and health-conscious consumers through OTC and direct-to-consumer channels.
Ownership category
akta.pro rank

Biolinq industry classification

Industry
Product category
Wearable Continuous Glucose Monitoring
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Other Measuring and Controlling Device Manufacturing (334519), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAHAHAA
Continuous Glucose Monitoring (CGM) Systems
Healthcare & Life Sciences/Medical Devices & Diagnostics/Diabetes Care Devices (CGM, Insulin Delivery)
SECONDARYCRACAQAE
Blood Glucose Monitoring Devices (Consumer CGM & Smart Glucometers)
Consumer Products & Retail/Consumer Electronics & Appliances Retail/Personal Health & Wellness Devices (Smart Scales, BP/ECG Monitors, Sleep Devices)
SECONDARYHLAHAHAL
Diabetes Care Device Accessories & Adhesives (Sensors/Pump Supplies)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Diabetes Care Devices (CGM, Insulin Delivery)
SECONDARYHDAHALAK
Biosensors & Lab-on-Chip (BioMEMS)

Keywords

  • Continuous glucose monitoring
  • Wearable biosensors
  • Metabolic health devices
  • Needle-free sensors
  • Diabetes monitoring technology

Where Biolinq is headquartered

Location

Headquarters

HQ city
San Diego
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Biolinq business model

Business model
GTM type
B2C
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Biolinq Shine Glucose Sensor: Wearable biosensor sold as a disposable device with continuous glucose monitoring capability. Revenue expected from device sales, likely with recurring disposable sensor replacement cycle. Initially targeted at adults with Type 2 diabetes not on insulin therapy.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Biolinq product offering

Product offering

Core offering

Biolinq develops and commercializes the Biolinq Shine, a needle-free wearable continuous glucose monitoring (CGM) biosensor. The device uses an intradermal electrochemical microsensor array positioned in the papillary dermis layer (approximately 0.2mm deep, 20x more shallow than conventional CGM sensors) to measure glucose from interstitial fluid without hypodermic needles. It integrates a color-coded LED display (blue/yellow) for real-time glucose status and automatically correlates glucose data with activity and sleep tracking. The product received FDA De Novo classification in September 2025, establishing a new regulatory category of autonomous wearable glucose sensors.

Product overview

Biolinq is a healthcare technology company pioneering precision multi-analyte wearable biosensors to improve metabolic health. The company's flagship product is the Biolinq Shine biosensor, a needle-free continuous glucose monitoring wearable that integrates glucose, activity, and sleep data in a single device. The system consists of the Biolinq Shine hardware sensor with an autonomous LED display and a companion mobile application that provides detailed trend analysis and personalized insights. The platform is designed for multi-analyte sensing expansion beyond glucose to include biomarkers such as lactate and cortisol.

Differentiator

Problem solved

Functional benefit

Brands

  • Biolinq Shine: First fully autonomous, needle-free glucose sensor with integrated LED display for real-time glucose feedback, combining glucose, activity, and sleep monitoring in a single device for people with Type 2 diabetes not on insulin therapy.

Products and services

  • Biolinq Shine A needle-free wearable biosensor that continuously monitors glucose levels using an array of microsensors up to 20 times more shallow than conventional continuous glucose sensors. Features an integrated LED color-coded display (blue for in-range, yellow for elevated) visible without a phone, and automatically tracks activity and sleep data. Designed for adults 22 years or older with type 2 diabetes not on insulin therapy.

Quantifiable outcome

  • First needle-free glucose sensor with integrated primary display receiving FDA De Novo classification
  • +2 more outcomes

Companies that use Biolinq

Customer profile

Segments2 records

Ideal customer profiles2 records

Biolinq technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

Feature4 records

Biolinq partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Amalgam RxcoreTechnology or Integration · 16 October 2025Amalgam Rx partnered with Biolinq to develop digital infrastructure for Biolinq Shine. Amalgam's platform enabled rapid software development supporting Biolinq's FDA regulatory process and future expansion plans for connected health solutions and personalized care.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Biolinq competitors and assessment

Company assessment

Direct peers

  • Dexcom: Dexcom is the U.S. market leader in continuous glucose monitoring, offering G6 and G7 CGM systems. Directly comparable as a CGM device maker targeting diabetes patients with needle-based wearable sensors, though serving broader populations including insulin-dependent users.
  • Abbott (FreeStyle Libre): Abbott's FreeStyle Libre is the global volume leader in CGM with factory-calibrated sensors. Direct competitor in the wearable glucose monitoring category, with a substantial non-insulin T2D user base that Biolinq also targets.
  • Senseonics: Senseonics develops Eversense, the first long-term implantable CGM with a 180-day sensor. Direct peer pursuing an alternative-format CGM approach with extended wear time, competing for differentiated glucose monitoring share.

Broad incumbents

  • Medtronic: Medtronic offers the Guardian CGM system integrated with its insulin pumps and closed-loop diabetes management portfolio. Broad incumbent in diabetes devices; former employer of Biolinq CEO Rich Yang.
  • Ascensia Diabetes Care: Ascensia is a focused diabetes care company offering CONTOUR blood glucose monitoring systems. A Series B investor in Biolinq and a broad incumbent in the diabetes monitoring category.
  • Insulet: Insulet makes the Omnipod tubeless insulin pump, an adjacent diabetes management device. Broad incumbent in diabetes care delivery with potential ecosystem overlap with CGM data.
  • Tandem Diabetes Care: Tandem develops the t:slim insulin pump with CGM integration for automated insulin delivery. Broad incumbent in diabetes management and a potential integration partner for Biolinq's data streams.
  • Roche Diabetes Care: Roche offers the Accu-Chek portfolio of blood glucose monitors and insulin delivery systems. Broad incumbent in diabetes monitoring with established pharmacy and payer channels relevant to Biolinq's OTC strategy.

Emerging players

  • Nemaura Medical: Nemaura is developing sugarBEAT, a non-invasive continuous glucose monitor using a skin patch. Emerging player pursuing needle-free CGM with partial overlap to Biolinq's needle-free approach.
  • EOFlow: EOFlow develops the EOPatch tubeless insulin pump and participated as an investor in Biolinq's Series B. Emerging player in wearable drug delivery with potential ecosystem partnership in diabetes care.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Biolinq social profiles

Digital presence

Biolinq compliance and trust

Trust signal

Compliance1 record

Biolinq financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Biolinq leadership team

Management profile

Number of profiles

Profiles18 records

Biolinq funding detail

Funding detail

Funding overview

Funding rounds9 records

Investors29 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Biolinq M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Biolinq

What does Biolinq do?

Biolinq develops and commercializes the Biolinq Shine, a needle-free wearable continuous glucose monitoring (CGM) biosensor. The device uses an intradermal electrochemical microsensor array positioned in the papillary dermis layer (approximately 0.2mm deep, 20x more shallow than conventional CGM sensors) to measure glucose from interstitial fluid without hypodermic needles. It integrates a color-coded LED display (blue/yellow) for real-time glucose status and automatically correlates glucose data with activity and sleep tracking. The product received FDA De Novo classification in September 2025, establishing a new regulatory category of autonomous wearable glucose sensors.

Is Biolinq a public or private company?

Biolinq is a private company. It is classified as venture growth investor backed and is currently operating.

When was Biolinq founded?

Biolinq was founded in 2012. It employs 101 to 250 people.

Where is Biolinq based?

Biolinq is headquartered in San Diego, United States, in the North America region.

How does Biolinq make money?

One revenue line is on record: biolinq Shine Glucose Sensor.

Who are Biolinq's main competitors?

Direct peers on record are Dexcom, Abbott (FreeStyle Libre) and Senseonics. Broad incumbents are Medtronic, Ascensia Diabetes Care, Insulet, Tandem Diabetes Care and Roche Diabetes Care. Emerging players are Nemaura Medical and EOFlow.

Does Biolinq have an API?

No public API is recorded for Biolinq.

What industry is Biolinq in?

Biolinq's product category is Wearable Continuous Glucose Monitoring. Its primary akta.pro industry code is HLAHAHAA, Continuous Glucose Monitoring (CGM) Systems, with a secondary code of CRACAQAE, Blood Glucose Monitoring Devices (Consumer CGM & Smart Glucometers). Its NAICS code is 334510 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The Times of IndiaA new glucose monitor shows your blood sugar on the patch itself, with no needle and no phone; here's how it worksBiolinq Shine is a needle-free glucose monitor that displays blood sugar on the patch itself, eliminating the need for a smartphone app. The FDA granted 510(K) clearance in September 2026, and it was named a Best Invention of 2026 by TIME. The device is intended for adults aged 22 and older not on insulin.Medical Device NetworkPodcast: Continuous monitoring’s burgeoning role in metabolic healthAbbott received CE mark and FDA approval for its Libre Duo 10-day dual glucose-ketone monitor, the first such device to reach the diabetes market. A podcast interview with BioLinq's Jared Tangney discusses continuous monitoring's role in diabetes and other metabolic conditions, including measuring cortisol, lactate, and ketones.YahooPodcast: Continuous monitoring’s burgeoning role in metabolic healthA GlobalData Healthcare podcast episode discusses the growing role of continuous monitoring devices in diabetes management, featuring BioLinq co-founder Jared Tangney. Abbott's Libre Duo dual glucose-ketone monitor received CE and FDA approvals in 2026, marking the first such device to reach the market. The episode also explores measuring biomarkers like cortisol and lactate for broader metabolic health.pharmaphorumLilly's rival to Novo's new Awiqli insulin gets FDA approvalThe FDA approved Eli Lilly's once-weekly basal insulin Onswik for adults with type 2 diabetes, six months after approving Novo's Awiqli. The approval adds competitive pressure to Novo's GLP-1 medicines, with Lilly launching Onswik in coming months. Pricing for Onswik has not been disclosed.Tracxn2026 Funding Rounds & List of InvestorsBiolinq has raised multiple funding rounds from 2014 to 2025, including Series A through Series C and grants. The most recent round was a Series C in March 2025, with a post-money valuation of $9.13 million and lead investors RiverVest and Venture Partners.IEEE SpectrumCortisol Could Be the Next Frontier for WearablesAdaptyx Biosciences reported at the American Diabetes Association's annual meeting what it claims is the first continuous measurement of free cortisol drawn straight from human skin, using a matchbook-size sensor patch with aptamer technology that tracks the hormone in real-time from subdermal fluid. The company plans to target patients with rare adrenal disorders first, with a larger goal of identifying hidden cortisol excess in hard-to-control type 2 diabetes patients, potentially steering treatment decisions without endless medication increases. Multiple companies including Level Zero Health, Biolinq, and BioSens8 are racing to develop continuous cortisol monitoring devices, though no aptamer-based diagnostic device has yet received FDA clearance.WebProNewsHow Over-the-Counter Glucose Monitors Are Reshaping Metabolic AwarenessThe FDA expanded clearance for Dexcom's Stelo Glucose Biosensor System to children as young as two years old on June 12, 2026, marking a significant expansion of over-the-counter continuous glucose monitors (CGMs) into the pediatric market. The article examines both the promise of these devices—providing real-time metabolic feedback to consumers without prescriptions—and complications including accuracy concerns, data privacy issues, and questions about clinical utility for healthy users without diabetes or prediabetes. Industry analysts predict the OTC segment will substantially expand the overall CGM market as traditional prescription and insurance barriers are removed, with new entrants like Biolinq's needle-free Shine device and partnerships such as Abbott's Lingo with Ultrahuman's platform intensifying competition.MedTech Dive4 diabetes tech execs on the future of multi-analyte glucose sensorsAbbott's Libre Duo dual-analyte sensor, measuring glucose and ketones, is planned for European launch later this year and an FDA submission. Dexcom, PercuSense, and Biolinq are also developing multi-analyte sensors, with PercuSense testing glucose, lactate, ketones, and tissue oxygen. Abbott aims to reduce diabetic ketoacidosis events by detecting rising ketones.DrugdeliverybusinessBiolinq data backs autonomous, needle-free CGMBiolinq presented clinical data at ADA 2026 supporting its needle-free continuous glucose monitor, which uses a microsensor array and color-coded LED display. The study of 190 wearers showed 87% intensive insulin users, 11.1% MARD, and no meaningful performance differences. The company also shared data on a continuous lactate sensor with low latency during exercise.LifesciencedailyFDA Cleared Wearable Devices: Clinical Trust GuideIn January 2026, the US Food and Drug Administration published guidance documents that loosened regulatory requirements for consumer wearables and AI-enabled clinical tools, effectively reversing a July 2025 warning letter position against WHOOP, Inc. and raising questions about how healthcare systems can distinguish clinically validated devices from unregulated wellness products. The article surveys FDA-cleared wearable categories including continuous glucose monitors (Abbott's FreeStyle Libre series, Dexcom's G6 and G7 systems), cardiac monitoring devices (Apple Watch, VitalConnect's VitalRhythm, CardioTag, Element Science's Jewel Patch), and emerging clinical wearables (AeviceMD, Masimo W1, Biolinq Shine), noting that 510(k) clearance represents a minimum evidentiary standard requiring further clinical evaluation before adoption. A FDA-CMS pilot programme launched in late 2025 aims to generate systematic real-world evidence on cleared digital health technologies in chronic disease care.